Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Optimer, Pfenex, OncoSec, & More
Posted by sandiegobiotech October 19th, 2012 .
No Comments

Venture funding for San Diego’s life sciences companies continued to flow at a healthy rate during the third quarter that ended in September, according to data released earlier today. We’ve got that…

[[Click headline to continue reading.]]

Drug Development, News, Syndication, Xconomy »

Kinsella Redux: Charting a Way Back for Life Sciences Startups
Posted by sandiegobiotech September 27th, 2012 .
No Comments

As a man of many talents, Avalon Ventures’ Kevin Kinsella has a tendency to apply a term from one of his fields of interests in a conversation about another. Kinsella’s career as a biotech venture…

[[Click headline to continue reading.]]

Drug Development, News, Syndication, Xconomy »

An Insider’s View on Raising Money from Life Sciences VCs
Posted by sandiegobiotech August 21st, 2012 .
No Comments

The life sciences venture capital industry is undergoing rapid change. Although many innovative ideas have been taken from the bench to scientific discovery to treating patients, funding today to…

[[Click headline to continue reading.]]

Drug Development, News, Syndication, Xconomy »

MediciNova Raises Capital Through $20M Stock Purchase Agreement
Posted by sandiegobiotech August 20th, 2012 .
No Comments

Aspire Capital, a Chicago-based fund that invests directly in public companies, has agreed to invest as much as $20 million in San Diego-based MediciNova (NASDAQ: MNOV) over the next two years….

[[Click headline to continue reading.]]

Drug Development, News, Syndication, Xconomy »

Halozyme Says Roche Work Unaffected by FDA Concerns over HyQ Program
Posted by sandiegobiotech August 6th, 2012 .
No Comments

San Diego’s Halozyme Therapeutics (NASDAQ: HALO) told analysts and investors today it cannot provide a new timeline for its derailed HyQ program until company officials can meet with FDA regulators….

[[Click headline to continue reading.]]

Drug Development, Drug Discovery, News, Syndication, Xconomy »

Xconomist of the Week: John Reed on Sanford-Burnham’s Drug Pipeline
Posted by sandiegobiotech August 3rd, 2012 .
No Comments

In the decade since John Reed stepped in as chief executive, San Diego’s Sanford-Burnham Medical Research Institute has basically doubled in size. The nonprofit research facility has added a campus…

[[Click headline to continue reading.]]

Drug Development, News, Syndication, Xconomy »

Regulatory Concerns Over Halozyme’s Flagship Product Trigger Selloff
Posted by sandiegobiotech August 1st, 2012 .
No Comments

Shares of Halozyme Therapeutics (NASDAQ: HALO) plunged by more than 55 percent this evening, after the 14-year-old biopharmaceutical said FDA regulators have raised concerns about the potential…

[[Click headline to continue reading.]]

Drug Development, News, Syndication, Xconomy »

Sophiris Moves to Unlock Blockbuster Potential in New Prostate Drug
Posted by sandiegobiotech July 10th, 2012 .
No Comments

In the vintage tic-tac-toe TV game show, The Hollywood Squares, one of the classic funny moments occurred when host Peter Marshall asks the question: “True or false—a pea can last as long as 5,000…

[[Click headline to continue reading.]]

Drug Development, News, Syndication, Xconomy »

SD Life Sciences Roundup: Arena, PatientSafe, MEI Pharma, & More
Posted by sandiegobiotech June 28th, 2012 .
No Comments

Here’s my roundup of new developments from San Diego’s life sciences cluster over the past week. —After initially rejecting a new drug application from San Diego’s Arena Pharmaceuticals (NASDAQ:…

[[Click headline to continue reading.]]

Biotechnology, Drug Development, Featured, Medical Device, SDBN Blog »

INNOVATION: Finding the way from ordinary to extraordinary
Posted by Jessica Yingling June 12th, 2012 .
No Comments

The biggest question in entrepreneurship is how does one take an idea and make it reality, make it something that’s tangible and positively affects an individual and society as a whole. This was the theme at March’s SDBN networking event with Organovo, sponsored by Invetech.
Invetech helps companies translate innovations into breakthrough products.  They work with diagnostics, life sciences, medical devices, industrial, consumer and clean-tech industries.  Based in Australia, Invetech opened an office in San Diego in 2008 and has worked with a number of local companies including Organovo.
From idea to …